Results 131 to 140 of about 5,125,322 (307)

Preventing Future Harm: Identifying the Drivers of an Unsafe Discharge to Improve Safety on an Inpatient Oncology Service. [PDF]

open access: yesJCO Oncol Pract, 2023
Roberts TJ   +6 more
europepmc   +1 more source

Tumor‐Derived Exosomal circAP2B1 Induces M2 Macrophage Polarization by Enhancing Mitochondrial Homeostasis to Promote Esophageal Squamous Cell Carcinoma Progression

open access: yesAdvanced Science, EarlyView.
ESCC‐derived exosomal circAP2B1 promotes tumor progression by reprogramming mitochondrial metabolism via the ESRRA/KPNA1/MFN2 axis to induce M2 polarization of macrophages. ABSTRACT Esophageal squamous cell carcinoma (ESCC) remodels the immunosuppressive tumor microenvironment via exosome‐mediated intercellular communication.
Yiru Wang   +5 more
wiley   +1 more source

Psycho-oncology best practice guidelines and a service perspective: conceptualising the fit and towards bridging the gap

open access: yes, 2011
The purpose of this paper is two-fold. Firstly, it provides a summary of psychooncology best practice guidelines from the UK, US, Australia and Canada.
Hession, Natalie   +2 more
core  

Analysis of pre-residency research productivity, dual degree status, and gender distribution of underrepresented minorities among a current United States radiation oncology junior resident class

open access: yes, 2019
Background: Among the most competitive medical subspecialties, representation of underrepresented minorities (African-American race and/or Hispanic ethnicity) among resident trainees has historically been low compared to their United States Census ...
Jaboin, Jerry J.   +3 more
core   +1 more source

TAB2 Causes Neuronal Damage by Aggravating Microglia‐Mediated Neuroinflammation in Parkinson's Disease

open access: yesAdvanced Science, EarlyView.
In microglia, STAT3 upregulates TAB2, which promotes NF‐κB activation through its NZF domain‐mediated recognition of K63‐linked ubiquitin chains, leading to inflammatory cytokine release and subsequent neuronal injury. Lumacaftor suppresses TAB2 expression and directly binds the TAB2‐NZF domain to interrupt K63 ubiquitin recognition, thereby blocking ...
Yanhao Zhao   +12 more
wiley   +1 more source

Real world outcomes of a virtual ocular oncology service in Scotland. [PDF]

open access: yesEye (Lond), 2023
Younus O   +4 more
europepmc   +1 more source

Time to Update-Requesting Inclusive Submission Categories for Oncology Research.

open access: yes
Time to update abstract submission categories to promote dissemination of global oncology research.Universitätsklinik für Radio ...
Segelov, Eva   +2 more
core   +1 more source

Single‐Dose TACE‐Like Injection of Sustained‐Release Panobinostat/IL‐12 Polymeric Microparticles is Effective in Preclinical Liver Cancer Models

open access: yesAdvanced Science, EarlyView.
A novel PLGA/PBAE polymer microparticle platform revolutionizes intermediate‐stage liver cancer treatment by co‐delivering panobinostat and IL‐12 via a single TACE‐like injection. This sustained‐release system overcomes tumor immunosuppression, triggers robust innate and adaptive immune responses, and establishes tertiary lymphoid structures ...
Hongzhe Yu   +7 more
wiley   +1 more source

Management of systemic lupus erythematosus and antiphospholipid syndrome during CAR-T therapy: insights from two clinical cases

open access: yesImmuno-Oncology and Technology
Background: Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are autoimmune disorders marked by the presence of pathogenic autoantibodies predominantly produced by B cells.
C. Normand   +12 more
doaj   +1 more source

Patients from the Oral Oncology Center, UNESP, Araçatuba with an indication for prosthesis

open access: yes, 2013
Head and neck tumors are a major health concern worldwide, due to their high incidence and mortality rates, particularly in developing countries. In Brazil, this type of cancer is commonly diagnosed and studies suggested that it may be the leading cause ...
Goiato, Marcelo Coelho   +14 more
core   +1 more source

Home - About - Disclaimer - Privacy